Navigation Links
Perrigo Announces Launch of Generic Version of Elestat®

ALLEGAN, Mich., Nov. 1, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that its partner, PharmaForce/Luitpold Pharmaceuticals, received final approval for Epinastine HCl ophthalmic solution, 0.05%, a generic version of Elestat®. Perrigo will commence shipment of the product immediately.

Elestat® is a sterile ophthalmic solution containing epinastine that is indicated for the prevention of ocular itching associated with allergic conjunctivitis. Estimated annual brand sales for the product prior to generic market formation were $30 million, according to Wolters Kluwer data.

Perrigo's Chairman and CEO Joseph C. Papa stated, "Perrigo is excited to launch another new product in the ophthalmic category, as part of our extended topical strategy. This product is another example of Perrigo's commitment to expand our portfolio and bring new products to market. It further demonstrates our strategy to deliver quality affordable healthcare products."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company to Attend the 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology
2. Perrigo Reports Record Quarterly Revenue and Adjusted Earnings and Raises Full Year Adjusted EPS Guidance
3. Perrigo Company Announces Quarterly Dividend
4. Perrigo Expands Infant Formula Distribution in China With Founder Group
5. Perrigo Company Will Release First Quarter Fiscal 2012 Results On October 27, 2011
6. Perrigo Company Confirms FDA Tentative Approval for Clobetasol Propionate Emulsion Foam
7. Perrigo to Host Analyst Day on October 5, 2011 at the TASE, Tel Aviv Stock Exchange in Tel Aviv, Israel
8. Perrigo to Host Analyst Day on September 27, 2011 at the NASDAQ MarketSite in Times Square
9. Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%
10. Perrigo Company Will Release Fourth Quarter Fiscal 2011 Results on August 16, 2011
11. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
Post Your Comments:
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 . ... --> Pharmaboardroom releases its new 98-page Mexico Healthcare and ... , a country of over 122 million people. --> ... people. --> It offers companies, investors, policymakers, and stakeholders ... the second largest pharma and healthcare market in Latin ...
(Date:11/30/2015)... and REHOVOT, Israel , ... specialty pharmaceutical company focused on acquiring and developing innovative ... announced the appointment of Keith A. Katkin ... Gregory J. Flesher , chief executive officer for ... building successful organizations.  As chairman, he will be able ...
Breaking Medicine Technology:
(Date:11/30/2015)... Viejo, CA (PRWEB) , ... November 30, 2015 , ... ... Cut Pro X . Choose from scrolling web-styled transitions to wipes with blur ... colors, transition direction and more. Seamlessly transition from one clip to the next ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... and Attendance/Workforce Management cloud-based solutions, announced today that it has renewed the ... the Application Development, demonstrating a “best-in-class” ability and commitment to meet Microsoft’s ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... to announce their strategic partnership at the Radiological Society of North America ... and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce their strategic partnership at the Radiological Society of North America (RSNA) ... global providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership ...
Breaking Medicine News(10 mins):